MAJOR HURDLES OF IMMUNE-CHECKPOINT INHIBITORS IN PANCREATIC DUCTAL ADENOCARCINOMA СтатьяAkhuba L., Tigai Z., Shek D.Cancer Drug Resistance. Том 6. 2023. С. 327-331
WHERE DO WE STAND WITH IMMUNOTHERAPY FOR ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA: A SYNOPSIS OF CLINICAL OUTCOMES СтатьяAkhuba L., Tigai Z., Shek D.Biomedicines. Том 10. 2022.
IMMUNE-CHECKPOINT INHIBITORS FOR METASTATIC COLORECTAL CANCER: A SYSTEMATIC REVIEW OF CLINICAL OUTCOMES СтатьяShek D., Akhuba L., Carlino M.S., Nagrial A., Moujaber T., Read S.A., Gao B., Ahlenstiel G.Cancers. Том 13. 2021.
NON-CODING RNA AND IMMUNE-CHECKPOINT INHIBITORS: FRIENDS OR FOES? СтатьяShek D., Read S.A., Akhuba L., Qiao L., Gao B., Nagrial A., Carlino M.S., Ahlenstiel G.Immunotherapy. Том 12. 2020. С. 513-529
